On World AIDS Day…

On World AIDS Day…

Dec 01, 2016

  • 7 million people are living with HIV, 40% don’t know their status
  • New HIV infections among children have declined by 50% since 2010.
  • The incidence of HIV/AIDS is increasing among young gay men.
  • UNAIDS released a report showing 18.2 million people are now on antiretroviral therapy. However, it found women aged between 15 and 24 were at great risk.
  • The number of people living with HIV on antiretroviral therapy has increased by about a third, 3 million more than the 15 million by 2014.
  • In high income countries, 31% of people living with HIV are now over the age of 50 due to antiretroviral therapy.
  • Recent updated UNAIDS estimates indicate that US$ 26.2 billion will be required for the AIDS response in 2020, with US$ 23.9 billion required in 2030.
  • Brazil represents the largest number of people living with HIV in Latin America at 47%. Worldwide, it is one of 15 countries which represent 75% of the global number of people living with HIV.
  • Western and central Africa are current areas of concern – they account for 18% of people living with HIV. Lack of treatment access means the area also accounts for 30% of all Aids-related deaths globally
  • In June 2016, GSK made a groundbreaking deal to make the HIV drug Tivicay available for Botswana’s national effort to test and treat as many citizens as possible.
  • Cipla offers free antiretroviral technology to any African nation looking to produce their own drugs. In 2001, India’s Cipla had introduced the world’s first 3-in-1 fixed dose combination (Stavudine, Lamivudine, and Nevirapine). Now, a third of people living with HIV in 115 countries are taking this drug.
  • Gilead Sciences Inc. has begun marketing its HIV treatment Truvada to prevent infection with the virus that causes AIDS.

Downloads

Article in PDF

Recent Articles
  1. Small interfering RNA (siRNA) Therapeutics
  2. Merck, Gilead teams up for HIV treatment; Bright Future for Sanofi/Regeneron’s Libtayo; Roche acq...
  3. What can be the scope of Medical Marijuana?
  4. Notizia
  5. Changing Dynamics of HIV-1 Treatment Market
yeztugo-for-hiv
Articles

Gilead YEZTUGO Makes History with First Twice-Yearly HIV Prevention Drug

pharma-news-for-incyte-gilead-archeus
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Incyte’s MONJUVI Combo Approved by FDA for Relapsed/Refractory Follicular Lymphoma; Gilead’s YEZTUGO Becomes First FDA-Approved HIV Prevention with 6-Month Protection; FDA Reviewing Incyte’s OPZELURA for Pediatric Atopic Dermatitis (Ages 2–11); Archeus Technologies Receives FDA Clearance for Prostate Cancer Therapy ART-101; Cycle Pharmaceuticals’ HARLIKU Gets First FDA Approval for Alkaptonuria

pharma-news-for-gilead-merck-astellas
Notizia - Recent Pharma, Healthcare and Biotech Happenings

Gilead and Merck Announce Encouraging Phase II Results of Islatravir and Lenacapavir Combo; REGENXBIO Highlights Positive Data from Phase II ABBV-RGX-314 Wet AMD Study at AAO 2024; FDA Greenlights Astellas’ VYLOY for Advanced Gastric and GEJ Cancer Therapy; Merck’s CAPVAXIVE Vaccine Yields Strong Immune Response in Adults Vulnerable to Pneumococcal Disease; FDA Postpones LUMAKRAS Colorectal Cancer Verdict to Early 2025

AIDS
HIV
HIV infection
WORLD AIDS DAY
loader
loader